A prospective phase II study of L-asparaginase- CHOP plus radiation in newly diagnosed extranodal NK/T-cell lymphoma, nasal type

Table 5 Study comparison with recent prospective studies of ENKTL

Author, year, country	Disease status	Study period	No. of patients	Treat	RT (Gy) Med. (Ran.)	CR rate	Survival
Author, year, country	Disease status	Study period	No. of patients	Treat	RT (Gy) Med. (Ran.)	CR rate	OS	PFS
Lin et al. 2013, China (this study)	Newly- diagnosed	2008- 2012	Total cohort: 38	CHOP-L ± RT	52 (40–60)	81.6%	80.1% (2 yr-)	81% (2 yr-)
			UNKTL: 36
			stage I/II: 30			90%	88.3%	89.5%
			stage III/IV: 6			50%	50%	50%
Kim et al. 2009, Korea	Newly- diagnosed, stage I/II, UNKTL	2006- 2007	30	CCRT + VIPD	40(40–52.8)	80%	86.3% (3 yr-)	85.2% (3 yr-)
Yamaguchi et al. 2009, Japan	Newly- diagnosed, stage I/II, UNKTL	2003- 2006	27	CCRT + DeVIC	50: stage I, 50.4: stage II	77%	78% (2 yr-)	67% (2 yr-)
Jaccard et al. 2011, France	Refractory, relapsed	2006- 2008	19	AspaMetDex	/	61%	Median OS: 12.2 months
Yamaguchi et al. 2011 Japan	Newly- diagnosed stage IV, Refractory, relapsed	2007- 2009	38	SMILE	/	45%	55% (1 yr-)	53% (1 yr-)

Abbreviations: No. number, RT radiotherapy, Med Median; Ran, Range, CR complete remission, OS, overall survival, PFS progression-free survival, yr year, UNKTL Upper aerodigestive tract NK/T- cell lymphoma, CCRT concurrent chemoradiotherapy, CHOP-L cyclophosphamide, vincristine, doxorubicin, dexamethasone, and L-asparaginase, VIPD etoposide, ifosfamide, cisplatin, and dexamethasone, DeVIC dexamethasone, etoposide, ifosfamide, and carboplatin, AspaMetDex, L-asparaginase, methotrexate, and dexamethasone, SMILE methotrexate, ifosfamide, dexamethasone, etoposide, and L-asparaginase.

ISSN: 1756-8722